NASDAQ:EOLSEvolus Stock Price, Forecast & News

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EOLS stock has decreased by 10.3% and is now trading at $5.30. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evolus.

Evolus is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Evolus.

Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.03. The company earned $10.50 million during the quarter, compared to analyst estimates of $16.91 million. Evolus had a negative return on equity of 197.30% and a negative net margin of 217.51%. View Evolus' earnings history.

8 analysts have issued 1 year price targets for Evolus' shares. Their forecasts range from $4.00 to $30.00. On average, they anticipate Evolus' stock price to reach $14.25 in the next twelve months. This suggests a possible upside of 168.9% from the stock's current price. View analysts' price targets for Evolus.

News coverage about EOLS stock has trended very negative recently, according to InfoTrie. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evolus earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutEvolus.

Evolus saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 3,790,000 shares, a decrease of 37.8% from the April 30th total of 6,090,000 shares. Based on an average trading volume of 629,000 shares, the days-to-cover ratio is presently 6.0 days. Currently, 17.3% of the company's shares are sold short. View Evolus' Current Options Chain.

Some companies that are related to Evolus include Kala Pharmaceuticals (KALA), G1 Therapeutics (GTHX), Retrophin (RTRX), Morphic (MORF), Ardelyx (ARDX), Assembly Biosciences (ASMB), Provention Bio (PRVB), Sinovac Biotech (SVA), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Vanda Pharmaceuticals (VNDA), Athersys (ATHX), Corbus Pharmaceuticals (CRBP), Crinetics Pharmaceuticals (CRNX) and Radius Health (RDUS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Canopy Growth (CGC), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA) and JD.Com (JD).

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (9.77%), BlackRock Inc. (4.88%), MFN Partners Management LP (4.21%), Stonepine Capital Management LLC (2.44%), Sphera Funds Management LTD. (1.63%) and State Street Corp (1.06%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik. View institutional ownership trends for Evolus.

EOLS stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., UBS Group AG, Global Retirement Partners LLC, and Janney Montgomery Scott LLC. Company insiders that have sold Evolus company stock in the last year include Lauren P Silvernail, and Rui Avelar. View insider buying and selling activity for Evolus.

EOLS stock was purchased by a variety of institutional investors in the last quarter, including MFN Partners Management LP, Tang Capital Management LLC, Stonepine Capital Management LLC, Sphera Funds Management LTD., Alyeska Investment Group L.P., Morgan Stanley, State Street Corp, and Citigroup Inc.. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar, Simone Blank, and Vikram Malik. View insider buying and selling activity for Evolus.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $5.30.

Evolus has a market capitalization of $178.76 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

The official website for Evolus is www.evolus.com.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]